S'abonner

Role of plasma and blood-cell co-metagenomic sequencing in precise diagnosis and severity evaluation of sepsis, a prospective cohort study in sepsis patients - 05/03/25

Doi : 10.1016/j.jinf.2025.106434 
Ying Zhu a, b, 1, Hui Miao c, 1, Jingjia Zhang a, 1, Zhi Jiang c, 1, Xiaobing Chu a, b, 1, Yingchun Xu a, Wenjia Tian c, Haotian Gao a, Yun Zhu c, Lifeng Li c, , Qiwen Yang a, d,
a Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China 
b Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China 
c Genskey Medical Technology Co., Ltd, Beijing, China 
d Key Laboratory of Pathogen Infection Prevention and Control, Peking Union Medical College, Ministry of Education, Beijing, China 

Corresponding author.⁎⁎Corresponding author at: Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical SciencesBeijingChina

Summary

Purposes

Sepsis caused great clinical burden all over the world. This study clarified the value of plasma metagenomic next-generation sequencing (p-mNGS) and blood cell mNGS (bc-mNGS) in sepsis diagnosis and evaluation.

Methods

One hundred and fourty-seven blood samples were collected from sepsis patients who met sepsis 3.0 criteria. Blood culture (BC), qPCR, p-mNGS, bc-mNGS and necessary routine assays were conducted. Taking BC and qPCR as reference, diagnosis performance of p-mNGS and bc-mNGS was analyzed. Blood transcriptome was conducted to evaluate the immunological response of patients in groups with different p/bc-mNGS results. Impact of antibiotic use on different methods was also analyzed.

Results

The p-mNGS demonstrated a sensitivity of 100% for bacteria/fungi and 97% for viruses, which was higher than bc-mNGS (88% for bacteria and fungi, 71% for viruses). However, bc-mNGS showed higher concordance with BC results, which indicated that co-mNGS (p-mNGS plus bc-mNGS) protocol increased sensitivity and was helpful to justify viable blood pathogens in sepsis patients. This study showed that p-mNGS(+) & bc-mNGS(+) samples represented more activated immunity response (low expression of interferon-induced genes and high expression of JAK-STAT pathway genes), poorer clinical laboratory indicators (higher Sequential Organ Failure Assessment, higher procalcitonin and higher C-reactive protein) and lower survival rate. This study also proved that the use of broad-spectrum antibiotics affected much less on p/bc-mNGS diagnostic ability than on BC.

Conclusions

This research highlighted the potential value of plasma and blood-cell co-metagenomic sequencing in precise diagnosis and severity evaluation of sepsis patients, which will benefit the management of sepsis patients.

Le texte complet de cet article est disponible en PDF.

Highlights

In sepsis diagnosis, p-mNGS exhibited the highest sensitivity and bc-mNGS were more consistent with blood culture.
The blood transcriptome analysis revealed the p-mNGS(+) & bc-mNGS(+) group presented an active immune response.
Patients with p-mNGS(+) & bc-mNGS(+) exhibited more severe infections and worse outcomes than others.
Prolonged antibiotic use reduced the positive rate of BC but minimally affected mNGS.

Le texte complet de cet article est disponible en PDF.

Keywords : Plasma, Blood-cell, Metagenomic next-generation sequencing, Sepsis, Intensive care unit


Plan


© 2025  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 90 - N° 3

Article 106434- mars 2025 Retour au numéro
Article précédent Article précédent
  • Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project
  • Yangyupei Yang, Maria Deloria Knoll, Carly Herbert, Julia C. Bennett, Daniel R. Feikin, Maria Garcia Quesada, Marissa K. Hetrich, Scott L. Zeger, Eunice W. Kagucia, Melody Xiao, Adam L. Cohen, Mark van der Linden, Mignon du Plessis, Inci Yildirim, Brita A. Winje, Emmanuelle Varon, Maria Teresa Valenzuela, Palle Valentiner-Branth, Anneke Steens, J. Anthony Scott, Larisa Savrasova, Juan Carlos Sanz, Aalisha Sahu Khan, Kazunori Oishi, Néhémie Nzoyikorera, J. Pekka Nuorti, Jolita Mereckiene, Kimberley McMahon, Allison McGeer, Grant A. Mackenzie, Laura MacDonald, Shamez N. Ladhani, Karl G. Kristinsson, Jackie Kleynhans, James D. Kellner, Sanjay Jayasinghe, Pak-Leung Ho, Markus Hilty, Laura L. Hammitt, Marcela Guevara, Charlotte Gilkison, Ryan Gierke, Stefanie Desmet, Philippe De Wals, Ron Dagan, Edoardo Colzani, Pilar Ciruela, Urtnasan Chuluunbat, Guanhao Chan, Romina Camilli, Michael G. Bruce, Maria-Cristina C. Brandileone, Krow Ampofo, Katherine L. O’Brien, Kyla Hayford, The PSERENADE Team
| Article suivant Article suivant
  • Genetic characterization of Haemophilus ducreyi from non-genital skin lesions in Cameroon
  • Philippe Ndzomo, Ala-Eddine Deghmane, Serges Tchatchouang, Rosanne Ngome, Aude Terrade, Mélanie Denizon, Michaël Falguieres, Oumar Doucoure, Tania Crucitti, Onana Boyomo, Michael Marks, Sara Eyangoh, Muhamed-Kheir Taha

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.